Research use only · Not for human consumptionPepwizard compares vendor pricing for research-grade compounds. Nothing on this site is medical advice. How we price.
Compound sheet
Fat Loss / Dual GIP/GLP-1
07.05.2026
FAT LOSSLow availability
Tirzepatide
Dual GIP/GLP-1 · 39aa · aka "Mounjaro / Zepbound"
“SURMOUNT-5 winner. 11 live offers.”
No offers tracked yet.
§ 01 — Spec
Amino acids
39
Half-life
~5 days
Admin
Subcutaneous once weekly
Typical dose
2.5 mg weekly, titrated up to 15 mg weekly
Live offers
0
§ 02 — Abstract
A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.
Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.
Studied for
0120%+ average bodyweight reduction over 72 weeks
02Superior glycaemic control vs semaglutide in head-to-head
03Improved sleep apnoea severity
04Reduced liver fat (MASLD)
§ Codes
Live coupon for Tirzepatide.
§ 03 — Stock
No approved vendor stocks Tirzepatide yet.
We only feature vendors whose affiliate programmes we've signed off — no inventory padding. We're onboarding more partners and will list Tirzepatide as soon as one stocks it.
Email me when it lists
We'll ping you the moment a tracked vendor lists Tirzepatide.
Free · weekly
Your email. That's it. No account. No tracking pixels. Unsubscribe anytime.
§ 04 — Trend
Tracking begins.
We started tracking Tirzepatide on 2026-05-07. The chart unlocks at 14 daily snapshots — currently 1 on file.
1 snapshot · floor on 07.05.2026